Key challenges for drugs in clinical development for cholangiocarcinoma
- PMID: 33530767
- PMCID: PMC11994244
- DOI: 10.1080/13543784.2021.1880565
Key challenges for drugs in clinical development for cholangiocarcinoma
References
-
- Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588. - PMC - PubMed
-
•• This is a very comprehensive review of the etiology, biology, and management of cholangiocarcinom, covering the spectrum of basic science to clinical knowledge.
-
- Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104–114. - PubMed
-
- Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical